If the justices take up the case, they could hear oral arguments early next year and issue a decision by late June 2024, influencing fall elections.
10/19/2023
by CARRIE N. BAKER
On Thursday, Oct. 12, a wide range of organizations filed 14 amicus curiae briefs supporting a Justice Department petition asking the U.S. Supreme Court to overturn a Fifth Circuit decision imposing nationwide limits on access to the abortion pill mifepristone. Supporting the government’s appeal were reproductive rights organizations, medical and legal experts, patient advocacy groups, 257 members of Congress, 23 states and D.C., over 600 state legislators, state and local governments and officials, and pharmaceutical industry representatives, including GenBioPro, which makes a generic form of mifepristone.
“This legal attack on medical abortion has no basis in law or fact,” said GenBioPro CEO Evan Masingill. “Decades of science support mifepristone’s safety and efficacy. GenBioPro firmly believes that all people, regardless of income, gender, race or geography, have a right to access evidence-based healthcare and safe and effective medicines, and that includes medical abortion.”
Continued: https://msmagazine.com/2023/10/19/supreme-court-abortion-pill-mifepristone/